No Matter What You Think of the U.S. Election Outcome…

By Alain J. Gilbert, Co-Chair, Bionest Partners   The U.S. Presidential election is over. No matter how you personally feel about the outcome, the fact of Donald Trump’s election is likely to be positive for the healthcare industry and biopharma…. Read »

From Disease Treatment to Patient Care: Thoughts from ESMO 2016

The theme of patient centricity and care that we discussed at this year’s ASCO continued this autumn at ESMO 2016.  The tagline of the conference was ‘From disease treatment to patient care,’ which according to the organizers, “intended to capture… Read »

Chan Zuckerberg Initiative Funds $3 Billion Science Effort to Cure or Manage All Diseases by 2100

On September 21, Facebook CEO and billionaire, Mark Zuckerberg, and his pediatrician wife, Dr. Priscilla Chan, announced a new, privately funded big science effort. The couple pledged more than $3 billion toward a plan to “cure, prevent or manage all… Read »

Blue Ribbon Panel Issues Cancer Moonshot Recommendations

On September 7, a Blue Ribbon Panel — composed of 28 top cancer researchers, oncologists, patient advocates and leaders from the private sector — issued 10 recommendations aimed at speeding up advances in cancer prevention, diagnosis, treatment and care. The… Read »

Mapping the Brain: Dawn of a New Era for Neuroscience Research?

On July 20, a team of neuroscience researchers from Washington University in St. Louis, Missouri and other centers published a precise new brain map in Nature — an outcome of the White House BRAIN (Brain Research through Advancing Innovative Neurotechnologies)… Read »

PRIME Launched by EMA to Speed Review and Approval of Innovative, “Breakthrough” Drugs

Four years ago, the US Food and Drug Administration launched its “breakthrough designation” program, designed to speed the review and potential approval of new therapeutics deemed to offer the possibility of substantial improvement over existing options for patients with life-threatening or… Read »

Running the Risks of High Stakes Drug Development

On August 5, Bristol-Myers Squibb (BMS) surprised many with the announcement that their PD-L1 inhibitor Opdivo® (nivolumab) had failed a Phase 3 trial assessing its use as a monotherapy in the first-line treatment of non-small cell lung cancer (NSCLC). This is a… Read »

Update on the “Cancer Moonshot”

In March, we wrote about the “Cancer Moonshot” Initiative that was announced as part of President Obama’s 2016 State of the Union Address. Headed by Vice President Joe Biden, the aim of the initiative was to facilitate collaboration in cancer… Read »

Not Quite What the Headlines Suggest: Some Comments on Drug Pricing Issues

We recently had the opportunity to participate in an industry roundtable discussion on pharmaceutical pricing, organized by the editors of Life Science Leader. The discussion included perspectives from members of the pharmaceutical and biotech industry, patient advocates (from FasterCures and… Read »

Collective Wisdom Around Oncology – Comments on ASCO 2016

The Bionest Oncology team spent a jam packed and exciting five days at ASCO 2016 earlier this month in Chicago.  More than 30,000 oncology professionals gathered from all around the world to discuss the latest data and innovations in oncology,… Read »

1 6 7 8 9 10